The ability to treat SARS-CoV-2 has changed the course of the pandemic, allowing for people who are potentially at higher risk of severe disease to be treated with antivirals which are aimed to limit viral replication. Paxlovid™ is a combination antiviral of nirmatrelvir and ritonavir which was authorized by the FDA for use in COVID-19 in December 2021. On July 6, 2022, the FDA authorized pharmacists to prescribe Paxlovid with certain limitations. This authorization has been met with both praise and criticism. Should pharmacists prescribe Paxlovid?
and please use this references:
1) Roberts JA et al. 2022. Pandora’s box: Paxlovid, prescribing, pharmacists and pandemic. https://onlinelibrary.wiley.com/doi/full/10.1002/jppr.1799
2)Marzolini et al. 2022. Recommendations for the Management of Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications. https://pubmed.ncbi.nlm.nih.gov/35567754/
3)Louis D Saravolatz, MD, MACP, FIDSA, Shawn Depcinski, PharmD, Mamta Sharma, MD, FACP, FIDSA, Molnupiravir and Nirmatrelvir-Ritonavir: Oral COVID Antiviral Drugs, Clinical Infectious Diseases, 2022;, ciac180, https://doi.org/10.1093/cid/ciac180
4)FDA. 2022. Coronavirus (COVID-19) Update: FDA Authorizes Pharmacists to Prescribe Paxlovid with Certain Limitations. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-pharmacists-prescribe-paxlovid-certain-limitations
5)Monica V. Mahoney PharmD1 , Hita Bhagat PharmD2 , Robbie Christian PharmD3 , Carlos del Rio MD4 , Kenneth C. Hohmeier PharmD5 , Michael E. Klepser PharmD6 and Jason M. Pogue PharmD7. Pharmacists as important prescribers of coronavirus disease 2019 (COVID-19) antivirals Published: July 11, 2022 by Cambridge University Press https://www.cambridge.org/core/journals/antimicrobial-stewardship-and-healthcare-epidemiology/article/pharmacists-as-important-prescribers-of-coronavirus-disease-2019-covid19-antivirals/D5CABEA8DB572AC14A7AD7551516E78E